RECURRENT CLASSIC HODGKIN LYMPHOMA
Clinical trials for RECURRENT CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested to fight Tough-to-Treat blood cancer
Disease control OngoingThis study is testing combinations of three drugs—brentuximab vedotin, nivolumab, and ipilimumab—to see if they work better together to control Hodgkin lymphoma that has come back or hasn't responded to previous treatments. It involves 146 patients aged 12 and older and aims to f…
Matched conditions: RECURRENT CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …
Matched conditions: RECURRENT CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC